Teva CEO Richard Francis expects continued growth for Austedo despite future Medicare price negotiations, maintaining $2.5B ...

Teva Pharmaceutical is a victim of its own success, Chief Executive Richard Francis said Wednesday as Teva stock plummeted on ...

Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite ...

Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

Central to its near-term growth plan is the performance of Austedo (deutetrabenazine), approved for Huntington’s disease and tardive dyskinesia, which Teva predicts will bring in $2.5 billion in ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...